(183 days)
The Fixone Biocomposite Anchors are intended for fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee and elbow in the following procedures:
Shoulder: Rotator Cuff Repair, Bankart Repair, Biceps Tenodesis, Acromio-Clavicular Separation Repair, Deltoid Repair. Capsular Shift or Capsulolabral Reconstruction:
Foot/Ankle: Lateral Stabilization, Medial Stabilization, Achilles Tendon Repair;
Knee: Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair. Posterior Oblique Ligament Repair. lliotibial Band Tenodesis:
Elbow: Biceps Tendon Reattachment, Ulnar or Radial Collateral Ligament Reconstruction.
The Fixone Biocomposite Anchor is intended for reattaching soft tissue to bone with sutures. The anchor is manufactured from biodegradable materials (PLGA copolymer and β-ΤCP). A nonresorbable suture manufactured from cobraided UHMWPE and PET fibers is inserted into the anchor is implanted using a provided driver.
This device is could used with instrument that manufactured by Aju Pharm Co.,Ltd. It is consist of 18 models. It provide non-sterile (user must sterilization before use).
The provided text describes a medical device, the "Fixone Biocomposite Anchor," and its 510(k) premarket notification. This document focuses on demonstrating substantial equivalence to a predicate device through bench testing and biocompatibility assessments, rather than presenting a study of AI/algorithm performance. Therefore, many of the requested criteria related to AI studies (e.g., sample size for test/training sets, ground truth establishment, expert adjudication, MRMC studies) are not applicable to this document.
However, I can extract information related to the acceptance criteria and the studies performed for this medical device.
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are primarily based on established international standards (ASTM, ISO, USP) and predefined limits for specific tests. The reported device performance for all listed tests is "Pass," indicating that the device met the established criteria.
| Test Item | Acceptance Criteria | Reported Device Performance |
|---|---|---|
| Bench Testing - Anchor Performance | ||
| External surface / Measurement | ASTM F2502 and USP<28> | Pass |
| Insertion torque | N/A (implied to meet predicate performance) | Pass |
| Fixation strength | N/A (implied to meet predicate performance) | Pass |
| Tensile strength | N/A (implied to meet predicate performance) | Pass |
| Extractable color | N/A (implied to meet predicate performance) | Pass |
| Extraction test - pH | The difference should be 1.5 and less. | Pass |
| Extraction test - Potassium permanganate reducing substances | The difference of the consumption of potassium permanganate should be 2.0 mL and less. | Pass |
| Extraction test - Residue after evaporation | Record the weight of the residue should be 1.0mg and less. | Pass |
| Extraction test - Heavy metals | Any brown color produced within 10 minutes in the tube containing the extract of the prepared sample does not exceed that in the tube containing the standard lead solution. | Pass |
| Extraction test - UV spectrum (250nm~350nm) | Maximum absorbance between 250 to 350 nm should be 0.1 and less. | Pass |
| Extraction test - Property | When observing it with the naked eye, test solution should be clear and have no foreign particles. | Pass |
| Performance comparison test (Fixone vs. Arthrex) - Insertion force | N/A (implied to demonstrate substantial equivalence to predicate) | Pass |
| Performance comparison test (Fixone vs. Arthrex) - Insertion torque | ASTM F2502 | Pass |
| Performance comparison test (Fixone vs. Arthrex) - Pull-out test | N/A (implied to demonstrate substantial equivalence to predicate) | Pass |
| Performance comparison test (Fixone vs. Arthrex) - Fatigue test | The anchor shall be inserted into the pilot hole. Apply the load 50% of Pull-out test (offset 10%, Sine shape) - 30° (worst case) | Pass |
| Performance Testing of Fixone® Biocomposite Anchor (Pull-out test) - Short Immersion (5min - 24hr) | Pull-out test by immersion time of saline solution to evaluate two bioabsorbable suture anchors. ASTM F1839-08, Standard specification for RGID Polyurethane Foam for Use as a Standard Material for Testing Orthopaedic Devices and Instruments. (Specific quantitative criteria not explicitly listed but implied successful comparison). | Pass |
| Performance Testing of Fixone® Biocomposite Anchor (Pull-out test) - Long Immersion (4 weeks - 26 weeks) | Pull-out test by immersion time of saline solution to evaluate two bioabsorbable suture anchors. ASTM F1839-08, Standard specification for RGID Polyurethane Foam for Use as a Standard Material for Testing Orthopaedic Devices and Instruments. (Specific quantitative criteria not explicitly listed but implied successful comparison). | Pass |
| Shelf-life testing | Real-time equivalent (RTE) and Accelerated aging temperature, Taa as per AAMI TIR17 and ASTM F 1980-02. Aging temperature: 55±2℃, aging time: 225 days. (Specific quantitative criteria not explicitly listed but implied successful demonstration of 5-year shelf-life). | Pass |
| Biocompatibility - Anchor | ||
| Cytotoxicity | ISO 10993-5(2009) Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity | Pass |
| Acute systemic toxicity test | ISO 10993-11(2009) Biological evaluation of medical devices - Part 11: Tests for systemic toxicity | Pass |
| Pyrogen Test | ISO 10993-11 Test for systemic toxicity, pyrogen test | Pass |
| Intracutaneous (intradermal) reactivity test | ISO 10993-10(2013) Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization | Pass |
| Maximization test for delayed hypersensitivity | ISO 10993-10(2013) Test for irritation and skin sensitization, Maximization test for delayed hypersensitivity | Pass |
| Bacterial reverse mutation test | ISO 10993-3, Genotoxicity test OECE 471, Bacterial reverse mutation test | Pass |
| Mammalian erythrocyte micronucleus test | ISO 10993-3, Genotoxicity test OECE 471, Bacterial reverse mutation test | Pass |
| Implantation test | ISO 10993-6, Tests for local effects after implantation, Annex D test methods for implantation in bone | Pass |
| Bioabsorbable screws test | ASTM F2502 Standard specification and test methods for bioabsorbable plates and screws for internal fixation implants | Pass |
| Subchronic toxicity test | ISO 10993-11 Biological Evaluation of Medical Devices Part 11- Test for systemic toxicity | Pass |
| Biocompatibility - Suture | ||
| Cytotoxicity | ISO 10993-5, Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity | Pass |
| Systemic toxicity test | ISO 10993-11, Biological evaluation of medical devices - Part 11: Tests for systemic toxicity | Pass |
| Pyrogen Test | ISO 10993-11 Test for systemic toxicity, pyrogen test | Pass |
| Intracutaneous reactivity test | ISO 10993-10, Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization | Pass |
| Maximization sensitization | ISO 10993-10, Test for irritation and skin sensitization, Maximization test for delayed hypersensitivity | Pass |
| Genotoxicity test | ISO 10993-3, Genotoxicity test OECE 471, Bacterial reverse mutation test | Pass |
| Implantation test | ISO 10993-6, Tests for local effects after implantation, Annex D test methods for implantation in bone | Pass |
| Hemolysis test | ISO 10993-4, Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood | Pass |
| Biocompatibility - Final Product | ||
| LAL test (Bacterial Endotoxin test) | USP 38 NF 33 <85> Bacterial Endotoxin test "Gel clot method" | Pass |
2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)
The document does not specify exact sample sizes for each particular bench test. It indicates that "Bench test were performed" and "The tests demonstrated that the device performs in a substantially equivalent manner to the predicate device." These tests are typically conducted in a laboratory setting.
- Sample Size: Not explicitly stated as a number of individual anchors or sutures. Each test would have involved a specific number of samples as per the relevant ASTM or ISO standard.
- Data Provenance: The document states "AJU Pharm Co.,Ltd. / Korea" as the manufacturer. The testing was likely conducted in a laboratory setting, presumably in Korea or by a certified testing facility contracted by the manufacturer. This is prospective data generation through controlled laboratory experiments.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not applicable. This is not an AI/algorithm study involving expert review of medical images or patient data. The "ground truth" for this device's performance is established by adhering to widely accepted engineering, biocompatibility, and material testing standards (ASTM, ISO, USP).
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
Not applicable. This is not an AI/algorithm study involving expert adjudication. The "adjudication" is inherent in the pass/fail criteria defined by the standardized testing methods.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is a medical device for orthopedic fixation, not an AI diagnostic or assistance tool.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done
Not applicable. This is a medical device, not an AI algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The "ground truth" is defined by the technical specifications and performance requirements established by recognized standards organizations (ASTM, ISO, USP) for medical devices of this type. For example:
- Bench Tests: Mechanical properties (e.g., insertion torque, pull-out strength, fatigue) are measured against predefined engineering limits or compared directly to a predicate device's performance.
- Biocompatibility Tests: Biological response (e.g., cytotoxicity, systemic toxicity, irritation, implantation response) is assessed against criteria specified in ISO 10993 series for acceptable biological safety.
- Shelf-life Tests: Stability over time is assessed against physical, chemical, and functional criteria at accelerated and real-time aging conditions according to AAMI TIR17 and ASTM F 1980-02.
8. The sample size for the training set
Not applicable. There is no training set as this is not an AI/machine learning device.
9. How the ground truth for the training set was established
Not applicable. There is no training set as this is not an AI/machine learning device.
{0}------------------------------------------------
March 11, 2020
Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text. The FDA is a federal agency responsible for regulating and supervising the safety of food, drugs, and other products.
AJU Pharm Co., Ltd. % Peter Chung President Plus Global 300 Atwood Street Pittsburgh, Pennsylvania 15213
Re: K192484
Trade/Device Name: Fixone Biocomposite Anchor Regulation Number: 21 CFR 888.3030 Regulation Name: Single/multiple component metallic bone fixation appliances and accessories Regulatory Class: Class II Product Code: MAI Dated: February 5, 2020 Received: February 11, 2020
Dear Mr. Chung:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
{1}------------------------------------------------
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
for
Laura Rose. Ph.D. Acting Assistant Director DHT6C: Division of Restorative, Repair and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known)
Device Name
Fixone Biocomposite Anchor
Indications for Use (Describe)
The Fixone Biocomposite Anchors are intended for fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee and elbow in the following procedures:
Shoulder: Rotator Cuff Repair, Bankart Repair, Biceps Tenodesis, Acromio-Clavicular Separation Repair, Deltoid Repair. Capsular Shift or Capsulolabral Reconstruction:
Foot/Ankle: Lateral Stabilization, Medial Stabilization, Achilles Tendon Repair;
Knee: Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair. Posterior Oblique Ligament Repair. lliotibial Band Tenodesis:
Elbow: Biceps Tendon Reattachment, Ulnar or Radial Collateral Ligament Reconstruction.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary [K192484]
1. Applicant
- Company : AJU Pharm Co.,Ltd. 1)
-
- Address : A-207, 697, Pangyo-ro, Seongnam-si, Gyeonggi-do, Korea
-
- Tel : 82-31-765-4420
-
- Fax : 82-31-602-7818
- Prepared date : Sep. 01, 2019 5)
-
- Contact person : Peter Chung, 412-512-8802
-
- Contact person address : 300, Atwood Street, Pittsburgh, PA, 15213, USA
-
- Submission date : Mar. 11, 2020
- ರು) Submission type : Traditional
-
- Prior related submissions : K171299
2. Device Information
-
- Trade name : Fixone Biocomposite Anchor
-
- Common name : Biodegradable Orthopedic Bone Screw
-
- Regulation name : Fastener, Screw, Fixation, Bone, Suture
-
- Product code : MAI
-
- Regulation number : 888.3030
- Class of device : Class II 6)
-
- Panel : Orthopedic
3. The legally marketed device to which we are claiming equivalence
K171299, Aju Pharm Co., Ltd. / Fixone Biocomposite Anchor
4. Device description
The Fixone Biocomposite Anchor is intended for reattaching soft tissue to bone with sutures. The anchor is manufactured from biodegradable materials (PLGA copolymer and β-ΤCP). A nonresorbable suture manufactured from cobraided UHMWPE and PET fibers is inserted into the anchor is implanted using a provided driver.
This device is could used with instrument that manufactured by Aju Pharm Co.,Ltd. It is consist of 18 models. It provide non-sterile (user must sterilization before use).
| Product name | Instrument / 20 model codes including Fixone.I.B-A/T450a |
|---|---|
| Intended use | The instrument of make the hole in the bone. |
| Manufacturer | AJU Pharm Co.,Ltd. / Korea |
| Characteristic | This device is provided as Non-sterile and Reusable device.This device is provided non-sterile. This device is user-sterilized. |
| Sterilization method | Autoclave / 132°C / 4min / 20 min dry |
5. Intended Use :
The Fixone Biocomposite Anchors are intended for fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee and elbow in the following procedures:
Shoulder: Rotator Cuff Repair, Bankart Repair, SLAP Lesion Repair, Biceps Tenodesis, Acromio-Clavicular Separation Repair, Deltoid Repair, Capsular Shift or Capsulolabral Reconstruction;
Foot/Ankle: Lateral Stabilization, Medial Stabilization, Achilles Tendon Repair;
Knee: Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair, Posterior Oblique Ligament Repair, Iliotibial Band Tenodesis;
Elbow: Biceps Tendon Reattachment, Ulnar or Radial Collateral Ligament Reconstruction.
6. Performance data:
- Bench test were performed. Bench testing included biocompatibility, mechanical testing 1)
{4}------------------------------------------------
including EO residues. The tests demonstrated that the device performs in a substantially equivalent manner to the predicate device. The following bench testing is performed to demonstrate the functionality is substantially equivalent.
| Test item | Requirements | Results |
|---|---|---|
| External surface | ||
| Measurement | ASTM F2502 and USP<28> | Pass |
| Insertion torque | ||
| Fixation strength | ||
| Tensile strength | ||
| Extractable color | ||
| Extraction test | ||
| pH | The difference should be 1.5 and less. | |
| Potassium permanganatereducing substances | The difference of the consumption of potassium permanganate shouldbe 2.0 mL and less. | |
| Residue after evaporation | Record the weight of the residue should be 1.0mg and less. | |
| Heavy metals | Any brown color produced within 10 minutes in the tube containing theextract of the prepared sample does not exceed that in the tubecontaining the standard lead solution | Pass |
| UV spectrum(250nm~350nm) | Maximum absorbance between 250 to 350 nm should be 0.1 and less. | |
| Property | When observing it with the naked eye, test solution should be clear andhave no forign particles. | |
| Performance comparision test of FIXONE and Arthrex suture anchor | ||
| Insertion force | ||
| Insertion torque | ASTM F2502 | |
| Pull-out test | Pass | |
| Fatigue test | The anchor shall be inserted into the pilot hole.Apply the load 50% of Pull-out test(offset 10%, Sine shape) - 30° (worstcase) | |
| Performance Testing of Fixone® Biocomposite Anchor (Pull-out test) | ||
| Pull-out test by immersion time of saline solution to evaluate two bioabsorbable suture anchors.[Absorption time (soaking time) : 5min, 1hr, 4hr, 8hr, 12hr, 24hr | ||
| ASTM F1839-08, Standard specification for RGID Polyurethane Foam for Use as a Standard Material for Testing Orthopaedic Devices and Instruments | Pass | |
| Performance Testing of Fixone® Biocomposite Anchor (Pull-out test) | ||
| Pull-out test by immersion time of saline solution to evaluate two bioabsorbable suture anchors.[Absorption time (soaking time) : 4 weeks, 6 weeks, 12 weeks and 26 weeks | ||
| ASTM F1839-08, Standard specification for RGID Polyurethane Foam for Use as a Standard Material forTesting Orthopaedic Devices and Instruments | Pass | |
| Shelf life testing | ||
| To make shelf life time, my company set Real-time equivalent (RTE) and Accelerated aging temperature, | ||
| Taa as per AAMI TIR17 and ASTM F 1980-02. | ||
| Aging temperature: 55±2℃, aging time: 225 days |
2) Biocompatibility
| Anchor | |||
|---|---|---|---|
| # | Test item | Test method / Test criteria | Test result |
| 1 | Cytotoxicity | ISO 10993-5(2009) Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity | Pass |
| 2 | Acute systemic toxicity test | ISO 10993-11(2009) Biological evaluation of medical devices - Part 11: Tests for systemic toxicity | Pass |
| 3 | Pyrogen Test | ISO 10993-11 Test for systemic toxicity, pyrogen test | Pass |
| 4 | Intracutaneous(intradermal) reactivity test | ISO 10993-10(2013) Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization | Pass |
| 5 | Maximization test for delayed hypersensitivity | ISO 10993-10(2013) Test for irritation and skin sensitization, Maximization test for delayed hypersensitivity | Pass |
{5}------------------------------------------------
| 6 | Bacterial revers mutationtest | ISO 10993-3, Genotoxicity test OECE 471, Bacterial reversemutation test | Pass |
|---|---|---|---|
| 7 | Mammalian erythrocytemicronucleus test | ISO 10993-3, Genotoxicity test OECE 471, Bacterial reversemutation test | Pass |
| 8 | Implantation test | ISO 10993-6, Tests for local effects after implantation, Annex Dtest methods for implantation in bone | Pass |
| 9 | Bioabsorbable screws test | ASTM F2502 Standard specification and test methods forbioabsorbable plates and screws for internal fixation implants | Pass |
| 10 | Subchronic toxicity test | ISO 10993-11 Biological Evaluation of Medical Devices Part 11-Test for systemic toxicity | Pass |
| Suture | |||
|---|---|---|---|
| # | Test item | Test method / Test criteria | Test result |
| 1 | Cytotoxicity | ISO 10993-5, Biological evaluation of medical devices - Part 5: Tests for invitro cytotoxicity | Pass |
| 2 | Systemic toxicity test | ISO 10993-11, Biological evaluation of medical devices - Part 11: Tests forsystemic toxicity | Pass |
| 3 | Pyrogen Test | ISO 10993-11 Test for systemic toxicity, pyrogen test | Pass |
| 4 | Intracutaneous reactivity test | ISO 10993-10, Biological evaluation of medical devices - Part 10: Tests forirritation and skin sensitization | Pass |
| 5 | Maximization sensitization | ISO 10993-10, Test for irritation and skin sensitization, Maximization testfor delayed hypersensitivity | Pass |
| 6 | Genotoxicity test | ISO 10993-3, Genotoxicity test OECE 471, Bacterial reverse mutation test | Pass |
| 8 | Implantation test | ISO 10993-6, Tests for local effects after implantation, Annex D testmethods for implantation in bone | Pass |
| 9 | Hemolysis test | ISO 10993-4, Biological evaluation of medical devices - Part 4: Selection oftests for interactions with blood | Pass |
Final product
| 1 | LAL test | USP 38 NF 33 <85> Bacterial Endotoxin test "Gel clot method" | Pass |
|---|---|---|---|
| LAL test was performed in final product that consist of anchor and suture. |
The performance tests demonstrated that Fixone Biocomposite Anchor performs in a substantially equivalent manner to the predicate device.
7. Predicate device comparison table
| Manufacturer | AJU Pharm Co.,Ltd. | AJU Pharm Co.,Ltd. | Remark |
|---|---|---|---|
| 510(k) No. | K171299 | N/A | |
| Indication for use | The Fixone Biocomposite Anchors are intended for fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee and elbow in the following procedures:Shoulder: Rotator Cuff Repair, Bankart Repair, SLAP Lesion Repair, Biceps Tenodesis, Acromio-Clavicular Separation Repair, Deltoid Repair, Capsular Shift or Capsulolabral Reconstruction;Foot/Ankle: Lateral Stabilization, Medial Stabilization, Achilles Tendon Repair;Knee: Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair, Posterior Oblique Ligament Repair, Iliotibial Band Tenodesis;Elbow: Biceps Tendon Reattachment, Ulnar or Radial Collateral Ligament Reconstruction. | The Fixone Biocomposite Anchors are intended for fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee and elbow in the following procedures:Shoulder: Rotator Cuff Repair, Bankart Repair, SLAP Lesion Repair, Biceps Tenodesis, Acromio-Clavicular Separation Repair, Deltoid Repair, Capsular Shift or Capsulolabral Reconstruction;Foot/Ankle: Lateral Stabilization, Medial Stabilization, Achilles Tendon Repair;Knee: Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair, Posterior Oblique Ligament Repair, Iliotibial Band Tenodesis;Elbow: Biceps Tendon Reattachment, Ulnar or Radial Collateral Ligament Reconstruction. | Same |
| Classification name | Fastener. Screw. Fixation, Bone, Suture | Fastener. Screw. Fixation, Bone, Suture |
{6}------------------------------------------------
Ajupharm Co., Ltd. / Fixone Biocomposite Anchor / 510(k) Summary / K192484
| Manufacturer | AJU Pharm Co.,Ltd. | AJU Pharm Co.,Ltd. | Remark |
|---|---|---|---|
| Trade name | Fixone Biocomposite Anchor | Fixone Biocomposite Anchor | Same |
| Model/type | 80 model codes including BAB-45001a | 161 model codes including BAB-45001a | N/A |
| Productconfiguration | Driver | Driver | Same |
| Anchor | Anchor | ||
| Suture | Suture | ||
| Material | PLGA(70%) + β-TCP(30%) | PLGA(70%) + β-TCP(30%) | Same |
| Anchor | |||
| Outside diameter | 4.5mm/4.75mm/5.5mm/5.75mm/6.5mm | 3.0mm/4.5mm/4.75mm5.5mm/5.75mm/6.5mm | Similar |
| Length of abchor | 14.6mm/15mm/15.7mm/16mm/16.8mm | 11.9mm/14.6mm/15mm/15.7mm16mm/16.5mm/16.8mm | Similar |
| Suture | |||
| Absorbable | Non-absorbable | Non-absorbable | Same |
| Suture diameter | 0.50~0.599 (USP size 2) | 0.50~0.599 (USP size 2) | Same |
| Material | Polyethylene | Polyethylene | Same |
| Sterilization | EO Gas sterilization | EO Gas sterilization | Same |
| According to ISO 11135: 2014 | According to ISO 11135: 2014 | ||
| Biodegradable | Yes | Yes | Same |
| Principle ofoperation | Manual | Manual | Same |
| Shelf-life | 5 years | 5 years | Same |
9. Conclusion
The device is investigated for function to compare the operation of function between Fixone Biocomposite Anchor and predicate devices.
Comparison results demonstrate that the specifications and performance of the device are substantially equivalent to the legally marketed predicate device.
Therefore, it is concluded that Fixone Biocomposite Anchor is substantially equivalent to the legally marketed predicate device.
§ 888.3030 Single/multiple component metallic bone fixation appliances and accessories.
(a)
Identification. Single/multiple component metallic bone fixation appliances and accessories are devices intended to be implanted consisting of one or more metallic components and their metallic fasteners. The devices contain a plate, a nail/plate combination, or a blade/plate combination that are made of alloys, such as cobalt-chromium-molybdenum, stainless steel, and titanium, that are intended to be held in position with fasteners, such as screws and nails, or bolts, nuts, and washers. These devices are used for fixation of fractures of the proximal or distal end of long bones, such as intracapsular, intertrochanteric, intercervical, supracondylar, or condylar fractures of the femur; for fusion of a joint; or for surgical procedures that involve cutting a bone. The devices may be implanted or attached through the skin so that a pulling force (traction) may be applied to the skeletal system.(b)
Classification. Class II.